Arcadia Biosciences Q2 Net Loss Widens to $6.27M on Financing Valuation Loss
RKDA sits 19% above its 52-week low of $0.497 on light trading volume (0.2× avg).
Summary
Arcadia Biosciences reported a Q2 net loss of $6.27 million, widening from the prior quarter's $4.4 million loss, driven by unrealized losses and a PIPE financing valuation loss. Revenue was flat year-over-year at $1.44 million due to inventory and shipping delays. The company ended the quarter with $4.2 million in cash after closing a $4 million private placement. This follows a Nasdaq delisting notice received on August 4 for trading below $1, and a preliminary proxy seeking shareholder approval for a reverse stock split. The widening loss and ongoing cash burn heighten concerns about the company's ability to continue as a going concern.
At the time of this announcement, RKDA was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.50 to $6.71. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.